Launched in 2018, the Patient Group Mentoring programme is a tailored mentorship programme dedicated to building capacity of a representative cohort of patient groups at the regional level.
The programme works with patient-driven organisations that face challenges in accessing opportunities, while having the minimum capacity to engage in the offered opportunities and clear potential for growth in their region and beyond.
The main objective of this programme is that patient groups are engaged and heard as a key partners in the cancer community and health systems, at the local, regional and global levels. Through tailored assistance to access capacity building opportunities and efforts to connect patient groups, UICC adapts its approach to the specific needs of patient groups in relevant regions.
Sponsored full membership
The programme is currently being deployed in two regions, Asia Pacific and Eastern Mediterranean. To learn more about the programme in these regions, we encourage you to visit the dedicated pages:
Launched in 2018 as a pilot initiative to respond to a voiced need in the Asia Pacific (APAC) region, the programme aims to ensure that patient groups have the knowledge, capacity and connections to make a difference in their own health systems and beyond.
This regional programme is part of the broader Breast Cancer Programme.
The Patient Groups Mentoring programme is kindly supported in 2023 by Amgen, Bristol Myers Squibb (BMS) and MSD.
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
Bristol-Myers Squibb is a global BioPharma company firmly focused on its mission to discover, develop and deliver innovative medicines to patients with serious diseases.
For more than a century, MSD, a leading global biopharmaceutical company, has been inventing for life, bring forward medicines and vaccines for the world’s most challenging diseases. MSD is a trade name of Merck & Co., Inc., Kenilworth, N.J., USA. Through their prescription medicines, vaccines, biologic therapies, and animal health products, they work with customers and operate in more than 140 countries to deliver innovative health solutions. MSD also demonstrates their commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. Today, MSD continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer’s disease and infectious diseases including HIV and Ebola.
Fostering an influential cancer community with the skills, knowledge, networks and resources to achieve effective cancer prevention and control.
UICC has been supporting the continuing education of cancer control professionals through online learning since 2014.
UICC has a long history of building capacity for cancer organisations globally through grant making.
Established in 1962, the Fellowships is one of UICC's oldest and most established portfolio of programmes.
The UICC's organisational leadership workstream is designed to provide leaders in cancer organisations at all levels with spaces to acquire new skills, and opportunities to collaborate and take action together.
UICC’s Cancer Advocates programme provides an opportunity for civil society organisations (CSOs) from low- and middle-income countries to gain the skills and knowledge to engage in national advocacy efforts for improved cancer control. The programme is available in English, French and Spanish.
UICC's Virtual Dialogues provide members, and the cancer community, with regular opportunities to connect, exchange knowledge, access expert insights, and share solutions from the comfort of one's office or home.
Share this page